Gilead Announces Intent to Submit New Drug Application for Filgotinib to U.S. Food and Drug Administration This Year

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul. 1, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that at a recent pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration(FDA), the company provided an...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials